Diabetic Macular Edema - Pipeline Insight, 2026
Description
DelveInsight’s, “Diabetic Macular Edema - Pipeline Insight, 2026” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Diabetic Macular Edema pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Diabetic Macular Edema: Overview
Diabetic macular edema (DME) is the accumulation of excess fluid in the extracellular space within the retina in the macular area, typically in the inner nuclear layer, outer plexiform, Henle’s fiber layer, and subretinal space. DME is one of the significant causes of irreversible visual impairment and subsequent permanent vision loss and blindness.
The symptoms of DME often develop gradually and may initially be subtle, but they progressively interfere with daily visual tasks. Patients commonly experience blurred or distorted central vision, making it difficult to read, recognize faces, or perform detailed work. Straight lines may appear wavy (a condition known as metamorphopsia), and colors can seem faded or washed out. As the condition worsens, individuals may notice dark or empty spots (scotomas) in their central vision and increased difficulty seeing clearly in low-light conditions.
The underlying pathophysiology of diabetic macular edema is secondary to the disruption of the BRB. The BRB isolates the photoreceptors of the retina from the ophthalmic vasculature. The BRB functions in a complex manner that involves several factors that work in tandem; however, many of the specific physiologic processes are poorly understood. The BRB involves two major compartments: an outer and inner barrier. Animal models have illustrated that the permeability of both compartments is disrupted after the onset of diabetes. Disruption of this barrier results in the accumulation of macular edema; however, the process is more complicated than this and also involves various inflammatory markers upregulated by AGEs, hyperglycemia, and diabetes. Diabetes also results in vasoconstriction, which upregulates VEGF expression. VEGF also results in macular edema and results in vasculogenesis, which results in further retinal disease.
Diabetes and subsequent hyperglycemia results in the formation of advanced glycation end products (AGEs). The specific etiology of diabetic retinopathy is unclear and likely, the result of many interplaying factors. AGEs are osmotically active, and they may be responsible for fluid accumulation in the macula. Diabetes also results in disruption of the blood-retinal barrier (BRB), and this is likely critical in the pathogenesis of diabetic associated macular edema. AGEs are also associated with increased inflammatory markers such as VEGF, leukocyte adhesion, and protein kinase C.
DME is evaluated using both traditional and advanced imaging techniques, with diagnosis relying on methods such as slit-lamp examination, fundus photography, fluorescein angiography, and especially Optical Coherence Tomography, which provides high-resolution assessment of retinal thickness and fluid accumulation. Diagnostic criteria include retinal thickening or exudates near the Macula, as defined by clinical guidelines. Early detection is enhanced by OCT and retinal thickness analysis, while angiography helps evaluate vascular leakage. In terms of management, treatment has evolved from laser photocoagulation, based on Early Treatment Diabetic Retinopathy Study guidelines, to more effective modern therapies. Currently, anti-VEGF agents are the first-line treatment, targeting abnormal vascular permeability. Additional options include intravitreal corticosteroids, subthreshold laser therapy, and vitrectomy in selected cases. Although laser therapy can stabilize vision, it is not curative, and newer pharmacological approaches have significantly improved outcomes.
""Diabetic Macular Edema - Pipeline Insight, 2026"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic Macular Edema pipeline landscape is provided which includes the disease overview and Diabetic Macular Edema treatment guidelines. The assessment part of the report embraces, in depth Diabetic Macular Edema commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Macular Edema collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Diabetic Macular Edema report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diabetic Macular Edema Emerging Drugs
Further product details are provided in the report……..
Diabetic Macular Edema: Therapeutic Assessment
This segment of the report provides insights about the different Diabetic Macular Edema drugs segregated based on following parameters that define the scope of the report, such as:
Diabetic Macular Edema: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic Macular Edema therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Macular Edema drugs.
Diabetic Macular Edema Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Diabetic Macular Edema: Overview
Diabetic macular edema (DME) is the accumulation of excess fluid in the extracellular space within the retina in the macular area, typically in the inner nuclear layer, outer plexiform, Henle’s fiber layer, and subretinal space. DME is one of the significant causes of irreversible visual impairment and subsequent permanent vision loss and blindness.
The symptoms of DME often develop gradually and may initially be subtle, but they progressively interfere with daily visual tasks. Patients commonly experience blurred or distorted central vision, making it difficult to read, recognize faces, or perform detailed work. Straight lines may appear wavy (a condition known as metamorphopsia), and colors can seem faded or washed out. As the condition worsens, individuals may notice dark or empty spots (scotomas) in their central vision and increased difficulty seeing clearly in low-light conditions.
The underlying pathophysiology of diabetic macular edema is secondary to the disruption of the BRB. The BRB isolates the photoreceptors of the retina from the ophthalmic vasculature. The BRB functions in a complex manner that involves several factors that work in tandem; however, many of the specific physiologic processes are poorly understood. The BRB involves two major compartments: an outer and inner barrier. Animal models have illustrated that the permeability of both compartments is disrupted after the onset of diabetes. Disruption of this barrier results in the accumulation of macular edema; however, the process is more complicated than this and also involves various inflammatory markers upregulated by AGEs, hyperglycemia, and diabetes. Diabetes also results in vasoconstriction, which upregulates VEGF expression. VEGF also results in macular edema and results in vasculogenesis, which results in further retinal disease.
Diabetes and subsequent hyperglycemia results in the formation of advanced glycation end products (AGEs). The specific etiology of diabetic retinopathy is unclear and likely, the result of many interplaying factors. AGEs are osmotically active, and they may be responsible for fluid accumulation in the macula. Diabetes also results in disruption of the blood-retinal barrier (BRB), and this is likely critical in the pathogenesis of diabetic associated macular edema. AGEs are also associated with increased inflammatory markers such as VEGF, leukocyte adhesion, and protein kinase C.
DME is evaluated using both traditional and advanced imaging techniques, with diagnosis relying on methods such as slit-lamp examination, fundus photography, fluorescein angiography, and especially Optical Coherence Tomography, which provides high-resolution assessment of retinal thickness and fluid accumulation. Diagnostic criteria include retinal thickening or exudates near the Macula, as defined by clinical guidelines. Early detection is enhanced by OCT and retinal thickness analysis, while angiography helps evaluate vascular leakage. In terms of management, treatment has evolved from laser photocoagulation, based on Early Treatment Diabetic Retinopathy Study guidelines, to more effective modern therapies. Currently, anti-VEGF agents are the first-line treatment, targeting abnormal vascular permeability. Additional options include intravitreal corticosteroids, subthreshold laser therapy, and vitrectomy in selected cases. Although laser therapy can stabilize vision, it is not curative, and newer pharmacological approaches have significantly improved outcomes.
""Diabetic Macular Edema - Pipeline Insight, 2026"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic Macular Edema pipeline landscape is provided which includes the disease overview and Diabetic Macular Edema treatment guidelines. The assessment part of the report embraces, in depth Diabetic Macular Edema commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Macular Edema collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Macular Edema R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic Macular Edema.
This segment of the Diabetic Macular Edema report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diabetic Macular Edema Emerging Drugs
- EYP-1901: EyePoint, Inc.
- CU06-1004: Curacle Co., Ltd.
- ASKG712: AskGene Pharma, Inc.
- AIV007: AiViva BioPharma, Inc.
Further product details are provided in the report……..
Diabetic Macular Edema: Therapeutic Assessment
This segment of the report provides insights about the different Diabetic Macular Edema drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Diabetic Macular Edema
- There are approx. 45+ key companies which are developing the therapies for Diabetic Macular Edema. The companies which have their Diabetic Macular Edema drug candidates in the most advanced stage, i.e. phase III include, EyePoint, Inc.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Diabetic Macular Edema: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic Macular Edema therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Macular Edema drugs.
Diabetic Macular Edema Report Insights
- Diabetic Macular Edema Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Diabetic Macular Edema drugs?
- How many Diabetic Macular Edema drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic Macular Edema?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Diabetic Macular Edema therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Diabetic Macular Edema and their status?
- What are the key designations that have been granted to the emerging drugs?
- EyePoint, Inc.
- Curacle Co., Ltd.
- AskGene Pharma, Inc.
- AiViva BioPharma, Inc.
- Bio-Thera Solutions
- Merck
- Innovent Biologics Technology Limited
- Ripple Therapeutics Pty Ltd
- 4D Molecular Therapeutics
- Boehringer Ingelheim
- Kyowa Kirin Co., Ltd.
- SciNeuro
- EnnovaBio
- Invirsa, Inc.
- Ashvattha Therapeutics, Inc.
- AbbVie
- Sam Chun Dang Pharm. Co. Ltd.
- Eclipse Life Sciences, Inc.
- Roche
- Frontera Therapeutics
- Ocugen
- Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.
- Jemincare
- EYP-1901
- CU06-1004
- ASKG712
- AIV007
- BAT5906
- MK-3000
- IBI302
- IBE-814
- 4D-150
- BI 1815368
- KHK4951
- SNP318
- ENN0403
- INV-102
- D-4517.2
- ABBV-RGX-314
- SCD411
- EC-104
- RO-7446603
- FT-003
- OCU200
- MS-553
- JMKX003948
Table of Contents
180 Pages
- Introduction
- Executive Summary
- Diabetic Macular Edema: Overview
- Introduction
- Signs and Symptoms
- Causes
- Pathophysiology
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Diabetic Macular Edema– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- EYP-1901: EyePoint, Inc.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- CU06-1004: Curacle Co., Ltd.
- Product Description
- Research and Development
- Product Development Activities
- Early Stage Products (Phase I)
- Comparative Analysis
- ASKG712: AskGene Pharma, Inc.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Diabetic Macular Edema Key Companies
- Diabetic Macular Edema Key Products
- Diabetic Macular Edema- Unmet Needs
- Diabetic Macular Edema- Market Drivers and Barriers
- Diabetic Macular Edema- Future Perspectives and Conclusion
- Diabetic Macular Edema Analyst Views
- Diabetic Macular Edema Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
